Analyst Ratings For Abeona Therapeutics (NASDAQ:ABEO)
Today, Citigroup Inc. initiated coverage on Abeona Therapeutics (NASDAQ:ABEO) with a Buy.
There are 8 buy ratings on the stock.
The current consensus rating on Abeona Therapeutics (NASDAQ:ABEO) is Buy (Score: 3.00) with a consensus target price of $19.71 per share, a potential 1.18% downside.
Some recent analyst ratings include
- 10/10/2017-Citigroup Inc. initiated coverage with a Buy rating.
- 10/9/2017-HC Wainwright Reiterated Rating of Buy.
- 10/6/2017-Cantor Fitzgerald Reiterated Rating of Buy.
- 9/14/2017-Royal Bank Of Canada initiated coverage with a Outperform rating.
- 6/22/2017-Jefferies Group LLC Reiterated Rating of Buy .
- 5/26/2017-FBR & Co Reiterated Rating of Buy.
Recent Insider Trading Activity For Abeona Therapeutics (NASDAQ:ABEO)
Abeona Therapeutics (NASDAQ:ABEO) has insider ownership of 6.80% and institutional ownership of 38.38%.
- On 9/20/2016 Todd Wider, Director, bought 5,000 with an average share price of $5.48 per share and the total transaction amounting to $27,400.00. View SEC Filing
- On 7/31/2015 Mark J Ahn, Director, bought 18,182 with an average share price of $5.50 per share and the total transaction amounting to $100,001.00. View SEC Filing
- On 1/26/2015 Mark J Ahn, Director, bought 25,000 with an average share price of $4.00 per share and the total transaction amounting to $100,000.00. View SEC Filing
- On 12/24/2014 Steven H Rouhandeh, Director, bought 250,000 with an average share price of $4.00 per share and the total transaction amounting to $1,000,000.00. View SEC Filing
Recent Trading Activity for Abeona Therapeutics (NASDAQ:ABEO)
Shares of Abeona Therapeutics closed the previous trading session at with shares trading hands.
